GOSS
GOSS clinical trials: Gossamer Bio, Inc.
Every trial on ClinicalTrials.gov where Gossamer Bio, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 10
- Trials linked
- 10
- As lead sponsor
- 0
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
GOSS on the catalyst calendar · GOSS registry changes
- Primary completion Sep 9, 2026ActualPhase 2NCT04816604Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)Gossamer Bio USA, Inc. · Pulmonary Arterial HypertensionTerminatedGOSSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 3NCT06274801Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)Gossamer Bio USA, Inc. · Pulmonary Arterial HypertensionRecruitingGOSSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 17, 2022ActualPhase 2NCT04456998GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. · Pulmonary Artery HypertensionCompletedGOSSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 11, 2023ActualPhase 1NCT05242146GB5121 in Adult Patients With Relapsed/Refractory CNS LymphomaGB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. · CNS LymphomaTerminatedGOSSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 11, 2022ActualPhase 1NCT04060342GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With...GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. · Pancreatic AdenocarcinomaTerminatedGOSSLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 5, 2021ActualPhase 1NCT03926793Clinical Study of Inhaled GB002 for Treatment of WHO Group I Pulmonary Arterial HypertensionGB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. · Pulmonary Arterial HypertensionCompletedGOSSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 23, 2020ActualPhase 2NCT03683576GB001 in Adult Subjects With Moderate to Severe AsthmaGB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc. · AsthmaCompletedGOSSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 9, 2020ActualPhase 2NCT03956862GB001 in Adult Participants With Chronic RhinosinusitisGB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc. · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)CompletedGOSSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 3, 2018ActualPhase 1NCT03473236Phase 1A Safety Trial of Inhaled PK10571 (GB002)GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. · Safety IssuesCompletedGOSSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 17, 2019ActualPhase 1NCT03860896GB004 in Adult Subjects With Active Ulcerative ColitisGB004, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. · Ulcerative ColitisCompletedGOSSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 10 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner